27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
: Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia). 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source
Of 204 normative reference models, 199 (97.5%) met the predefined diagnostic criteria; median held-out explained variance (EXPV) was 0.174. 2 key findings →
Design: longitudinal study Participants: 111 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Aging is the greatest risk factor for Alzheimer's disease (AD), yet how and when AD-related pathological progression diverges from aging remains poorly understood. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease pathology and cognitive outcomes frequently diverge, yet current single-axis definitions cannot identify resilient (high pathology, preserved cognition) and resistant (high risk, low pathology) subgroups reliably at scale, obscuring the mechanisms that uncouple pathological burden from cognitive decline. 2 key findings →
Participants: 1,009 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease and cerebral amyloid angiopathy are characterized by the accumulation of amyloid-β (Aβ) species, yet the human fluid-physiological mechanisms that regulate soluble Aβ transport and clearance remain poorly understood. 3 key findings →
Participants: 502 Evidence: moderate
Full summary, score breakdown and related studies → Original source
As the world's population ages, Alzheimer's disease (AD), a progressive neurodegenerative disorder, is becoming more common. 1 key finding →
Participants: 59 Evidence: low
Full summary, score breakdown and related studies → Original source
Residualized WMH T1w/T2w-FLAIR ratio captures lesion-specific microstructural variation missed by volumetric measures, consistent with vascular-gliotic injury in VD and coexisting amyloid-linked demyelination in AD. 4 key findings →
Design: cross-sectional Participants: 71 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Structured Abstract INTRODUCTION Alzheimer’s disease (AD) progresses over decades, yet plasma biomarkers that resolve disease stage rather than simply detect disease remain scarce. 3 key findings →
Participants: 90 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Genetic risks were primarily associated with Aβ and tau pathology, clinical risks with neurodegeneration, and SDoH risks with cognition, suggesting that risk factors exert differential effects on AD pathophysiology. 5 key findings →
Design: cohort study Participants: 2,276 Evidence: moderate
Full summary, score breakdown and related studies → Original source
DPM is fundamentally constrained by dynamic range, variability, and test–retest reliability of the biomarker of interest. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Semi-supervised multimodal fusion improves prediction and reveals interpretable imaging patterns that predict APOE4 and clinical diagnoses better than traditional approaches. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Shorter sleep duration and greater REM sleep variability may index early AD-related brain changes, warranting longitudinal studies to establish their prognostic significance. 2 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source
Under nested cross-validation, the WWL kernel achieves a balanced accuracy of $0.651\pm0.028$, significantly outperforming both a raw-feature SVM and a histogram-based WL-kernel baseline. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Precision medicine approaches require physiological effects to be informative when translated to the individual. 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder, and early diagnosis is essential for timely intervention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Accurate differential diagnosis between Alzheimer’s disease (AD) and frontotemporal dementia (FTD) is of critical importance for the early screening of neurodegenerative diseases. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The social, structural, and physical conditions in which individuals live, work, and age, collectively termed social determinants of health (SDOH), are associated with risk of Alzheimer's disease and related dementias (ADRD). 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s Disease (AD) changes how the brain’s electrical activity behaves, and these changes can, in principle, be picked up directly from a resting-state EEG recording without any invasive testing. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuropsychiatric symptoms (NPS) are highly prevalent in Mild Cognitive Impairment (MCI), conceptualized as an intermediate clinical state between normal aging and dementia. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dynamic functional network connectivity (dFNC) commonly identifies recurring connectivity states from resting-state fMRI, but states derived independently in each dataset lack guaranteed correspondence across studies and cannot be directly estimated in new participants. 5 key findings →
Design: post-hoc analysis Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study investigated volumetric MRI differences of the thalamic nuclei in asymptomatic young adult C9orf72 expansion carriers compared to non-carriers, and examined spatial associations with normative thalamic transcriptomics from 8 weeks post-conception through middle age. 3 key findings →
Participants: 72 Evidence: low
Full summary, score breakdown and related studies → Original source
For more than 150 years, since the idea that mental illness is rooted in the brain first emerged in the mid-1800s, psychiatry has searched for a reliable biological system to anchor its understanding of mental illness. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Resting-state EEG is a scalable modality for neurophysiological screening, but conventional spectral descriptors capture only part of the signal organization altered in neurodegenerative disease. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
The disorders fell into one of three categories based on the topographic relationship of the disease-specific and healthy networks. 5 key findings →
Participants: 1,117 Evidence: low
Full summary, score breakdown and related studies → Original source
Electroencephalography (EEG) records cortical activity with high temporal resolution without radiation and at low cost, which makes it a practical signal for automated screening of neurological disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →